A common feature of many infections is that many pathogen-specific memory T cells become established in diverse nonlymphoid tissues. A mechanism that promotes the retention and survival of the memory T cells in diverse tissues has not been described. Our studies show that the collagen binding alpha1beta1 integrin, VLA-1, is expressed by the majority of influenza-specific CD8 T cells recovered from nonlymphoid tissues during both the acute and memory phases of the response. Antibody treatment or genetic deficiency of VLA-1 decreased virus-specific CTL in the lung and other nonlymphoid tissues, and increased them in the spleen. In spite of the increase in the spleen, secondary heterosubtypic immunity against flu was compromised. This suggests that VLA-1 is responsible for retaining protective memory CD8 T cells in the lung and other tissues via attachment to the extracellular matrix.
IntroductionAmong human cancers, B-cell lymphomas appear among the most susceptible to immunotherapeutic strategies, because of their high rate of response to monoclonal antibodies (mAbs) targeting the B-cell differentiation antigen CD20 and encouraging results from early phase clinical trials of tumor-specific therapeutic vaccines. 1 The availability of both passive and active immunotherapeutic agents against B-cell lymphomas has made them an important testing ground for the development of clinically effective immunotherapies in humans. [1][2][3] The best characterized target for active immunotherapy of B-cell lymphoma is tumor-specific immunoglobulin (idiotype, Id). 4 Immunization of patients with Id protein derived from their own tumors can elicit humoral and T cell-mediated immune responses associated with improvements in survival and tumor burden. [5][6][7][8] Traditional Id vaccines consist of Id protein chemically conjugated to the highly immunogenic carrier protein keyhole limpet hemocyanin (KLH) and injected together with an immunologic adjuvant. 1 Because of their potent antigenpresenting properties, 9 dendritic cells (DCs) have been used to augment lymphoma vaccine effectiveness, and durable tumor regressions have been observed after immunization with Id-loaded DCs. 10,11 Granulocytemacrophage colony-stimulating factor (GM-CSF), a DC growth and maturation factor, has also been used as an effective adjuvant in Id-KLH vaccines. 4,7,12 However, despite the elegant nature of the Id vaccine approach, shortcomings of this strategy include the requirement of producing a custom-made protein for each patient and limitation of the antitumor response to a single antigen. In contrast, vaccines using whole tumor cells offer the opportunity to elicit immunity against the entire collection of antigens expressed by the tumor. Pulsed DC vaccination using apoptotic tumor cells or lysates has emerged as a popular strategy for immunization against tumors in a variety of preclinical and human studies. While killed tumor cells in the form of apoptotic bodies or freeze-thaw lysates alone display limited immunogenicity, DCs loaded with these preparations have been found to elicit antitumor immunity in a variety of preclinical models [13][14][15][16] and early clinical trials. [17][18][19][20][21] Other strategies using DCs to present the full repertoire of tumor antigens expressed by tumor cells include fusion with tumor cells 22 or pulsing with tumorderived RNA. 23 The goal of these approaches is to achieve processing and presentation of exogenous cell-derived antigenic peptides by professional antigen-presenting cells (ie, "crosspresentation"), thereby evoking a CD8 ϩ T-cell antitumor response. 24 One attractive strategy for increasing tumor antigen crosspresentation is the targeting of IgG-complexed antigens into DCs via Fc␥ receptors. 25 Antigen-antibody complexes internalized via Fc␥ receptors at the DC surface efficiently enter both the MHC class I 26-28 and class II 29,30 antigen-presentation pathways. Several investi...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.